跳至主要内容
临床试验/JPRN-UMIN000010578
JPRN-UMIN000010578已完成未知

Study of efficacy of aflibercept in neovascular age-related macular degeneration (wAMD) with refractory of ranibizumab - Study of aflibercept in wAMD with refractory of ranibizumab

agoya City University Graduate School of Medical Sciences0 个研究点目标入组 50 人开始时间: 2013年4月26日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
50years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Greatest Linear Dimension (GLD) of the total lesion area <12 Macular Photocoagulation Study Disc Areas 2) Prior treatment with photodynamic therapy (PDT) within the past 3 months or more than 4 prior PDT treatment 3) Presence of RPE tears, or subretinal hemorrhage, scar or macular fibrosis (>50% lesion area area) 4) Prior treatment with aflibercept 5) Prior treatment with triamcinolone within 6 months 6) Prior treatment with dexamethasone within 30 days 7) Intraocular surgery within 6 months, vitrectomy surgery, submacular surgery, or other surgical intervention for AMD 8) Active intraocular inflammation 9) Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products

研究者

发起方
agoya City University Graduate School of Medical Sciences

相似试验